أصدرت شركة Tenaya Therapeutics, Inc. عرضاً تقديمياً في 17 مايو 2026، يغطي نتائج المرحلة الأولى/الثانية من دراسة RIDGE-1 للعلاج الجيني TN-401. ويركز العرض التقديمي على علاج اعتلال عضلة القلب البطيني الأيمن المحدث لاضطراب النظم المرتبط بـ PKP2.
أصدرت الشركة العرض التقديمي بالتزامن مع مراجعة البيانات السريرية، حيث يوفر تفاصيل حول الدراسة الجارية للمرشح للعلاج الجيني المتداول تحت الرمز TNYA في بورصة ناسداك (NASDAQ). لم يتم تحديد أي نتائج إضافية أو أعداد للمشاركين في مواد البيان الصادر.
من إعداد الذكاء الاصطناعي صورة مولدة بواسطة الذكاء الاصطناعي تم التحقق من الحقائق
A single, under-the-skin dose of the investigational RNA-interference drug zilebesiran lowered blood pressure when added to standard therapy in adults whose hypertension remained uncontrolled, according to results from the global Phase 2 KARDIA-2 trial of 663 participants published in JAMA.
Inovio Pharmaceuticals held its first-quarter 2026 earnings call on May 13 to discuss financial results for the period ended March 31 and provide updates on its DNA medicines platform.
من إعداد الذكاء الاصطناعي
ProQR Therapeutics N.V. published its slide deck for a presentation at the TIDES USA 2026 conference. The materials were released on May 15, 2026, in connection with the company's Q1 earnings summary from May 12.
A new treatment called Daraxonrasib has shown strong results against advanced pancreatic cancer in a recent clinical trial. The drug targets a genetic mutation long considered impossible to treat effectively.
من إعداد الذكاء الاصطناعي
ARS Pharmaceuticals held its first quarter 2026 earnings conference call on May 15, highlighting early momentum in the new year. Company executives emphasized growth drivers including expanded access for its neffy product. The call featured forward-looking statements about the firm's commercial progress.
A needle-free, DNA-based vaccine candidate designed using machine-learning methods has completed a first-in-human Phase 1 study in the UK, with researchers reporting it was well tolerated and induced immune responses against multiple viruses in the sarbecovirus group, which includes SARS-CoV, SARS-CoV-2 and related bat coronaviruses.
من إعداد الذكاء الاصطناعي
Enhanced Group Inc. started trading on the NYSE in early May following its combination with Paradise Acquisition Corp. The telehealth firm focuses on peptides and performance-enhancing products.